{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000007","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.042317+00:00","generated_at":"2026-06-20T17:40:45.259246+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance","bullets":["Total test reports in 2022: 44,338, up 58% YoY from 28,118.","DecisionDx-Melanoma volume 27,797 (+37% YoY); DecisionDx-SCC 5,966 (+70% YoY).","Year-end cash & short-term investments ~$259M ($123M cash + $136M short-term).","Q4 2022 test reports 12,563 (+52% YoY from 8,242); TissueCypher and IDgenetix newly contributed."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000007","json":"https://secwatch.observer/filing/0001447362-23-000007.json","markdown":"https://secwatch.observer/filing/0001447362-23-000007.md","text":"https://secwatch.observer/filing/0001447362-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/cstl-20230108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:40:45.259246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"336e722d1bf0f84dd1e31210caa5efeeba537e3d","claim":"CASTLE BIOSCIENCES INC updated its the year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"The Company expects to meet or exceed the top end of its previously guided range of $132–137 million for full-year 2022 total revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"fbbc1eb807bb25454a665d9a7fc78272404cd5ce","claim":"CASTLE BIOSCIENCES INC reported preliminary financial results for the fourth quarter of 2022.","evidence_excerpt":"On January 8, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing certain preliminary performance results for the fourth quarter of 2022 and for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}